L'activation des a-sécrétases (une nouvelle stratégie thérapeutique pour le traitement du traumatisme crânien)

La gravité du traumatisme crânien (TC) dépend de la sévérité immédiate des lésions primaires mais également de leur aggravation dans les heures et les jours qui suivent le TC, avec l apparition de lésions secondaires. La neuro-inflammation constitue l une des cascades physiopathologiques post-TC dont le contrôle a été décrit comme une stratégie neuroprotectrice potentielle. Elle compromet le taux de la forme soluble a du précurseur du peptide ß amyloÏde, sAPPa, un neuroprotecteur endogène issu de l action des enzymes a-sécrétases (ADAMs). Dans ce contexte, mon travail de thèse a eu pour but d étudier l intérêt thérapeutique des composés pharmacologiques modulant le taux de sAPPa post-TC sur les conséquences biochimiques, histopathologiques et fonctionnelles, à court et à long terme, dans un modèle de TC par percussion mécanique chez la souris. Parmi les différents composés, la minocycline, une tetracycline de 2e génération aux effets anti-inflammatoires, et l étazolate, une pyrazolopyridine récemment décrite comme activateur des a-sécrétases, ont été sélectionnés. Le traitement anti-inflammatoire par la minocycline permet de restaurer le taux de la sAPPa, et cet effet dans la phase précoce est accompagné d une réduction des conséquences histopathologiques (atrophie callosale et striatale, lésion des bulbes olfactifs et ventriculomégalie) à 3 mois post-TC. Sur le plan fonctionnel, le test d aversion olfactive a été pour la première fois mis au point sur un modèle expérimental de TC et a permis de révéler un déficit olfactif persistant dans notre modèle. De plus, un déficit cognitif persistant a été également mis en évidence par le test NORT Novel Object Recognition Test . Le même traitement par la minocycline a permis de corriger ces déficits olfactif et cognitif à court et à long terme (3 mois) post-TC. Les résultats obtenus sur l étazolate (étude de fenêtre thérapeutique, étude d effet-dose) ont montré, pour la première fois dans un modèle de lésion cérébrale, son potentiel anti-inflammatoire et anti-œdémateux, associé à la restauration du taux de la sAPPa, avec une fenêtre thérapeutique d au moins de 2h. Le même traitement réduit les conséquences histopathologiques (activation microgliale, ventriculomégalie, lésion des bulbes olfactives) et fonctionnelles (hyperactivité locomotrice, déficit cognitif), à court à long terme (3 mois) post-TC. En conclusion, l ensemble de ce travail a permis d établir les bénéfices d une stratégie pharmacologique s opposant à la fois à la neuro-inflammation et à la chute du taux de la sAPPa dans la phase précoce de TC avec une amélioration histologique et fonctionnelle à long terme, soulignant son intérêt thérapeutique. Il est important de souligner que la minocycline est déjà entrée en essai clinique pour le traitement de TC, et que malgré le peu de données précliniques, l étazolate (EHT-0202) est tout récemment entré en phase II pour le traitement de la maladie d Alzheimer.The severity of the sequelae of traumatic brain injury (TBI) depends on the extent of primary damage as well as the implication of secondary injury cascades that are triggered within the hours and days post- insult. Neuroinflammation is an important post-TBI cascade whose inhibition has been described as a potential neuroprotective strategy. Neuroinflammation has been associated to the decrease of an endogenous neuroprotector, the soluble form a of the amyloid precursor protein (sAPPa), generated by the activity of the enzymes a-secretases or ADAMs. The aim of this work was to evaluate the therapeutic interest of pharmacological compounds that restore sAPPa levels on short- and long-term biochemical, histological and functional outcome in a mouse model of TBI by mechanical percussion. Among the potential candidates, the compounds selected were minocycline, a tetracycline that exerts anti-inflammatory activity, and etazolate, a pyrazolopyridine that activates a-secretases. The anti-inflammatory treatment with minocycline was able to restore post-TBI sAPPa levels, and this acute effect was accompanied by lasting neuroprotection, namely reduction of lesion size (corpus callosum, striatum and olfactory bulbs) and ventriculomegaly and attenuation of glial reactivity. The olfactory aversion test, developped for the first time in experimental TBI, unraveled a persistant olfactory deficit. Moreover, a durable cognitive deficit was revealed by the Novel Object Recognition Task (NORT). Treatment with minocycline was able to attenuate both the olfactory and cognitive deficits in an effective manner. Moreover, the results obtained in the pharmacological study with etazolate (therapeutic window, dose-response) demonstrated, for the very first time, the anti-inflammatory and anti-oedematous efficacy of etazolate, when administered at least 2 hours post-TBI. The same treatment protocol was also able to attenuate sAPPa levels and offered persistent neuroprotection, namely reduction of lesion size (ventriculomegaly, olfactory bulb lesion) and microglial activation, and attenuation of functional deficits (hyperactivity, cognitive deficit). In conclusion, the findings of this work highlight the therapeutic efficacy of compounds that attenuate neuroinflammation and restore sAPPa levels within the acute and critical post-TBI aftermath, on histological and functional outcome. It is worth noting that minocycline is actually in a clinical trial for the treatment of traumatic brain injury and etazolate (EHT 0202), despite the poor experimental data available, has managed to enter a clinical trial for the treatment of Alzheimer s disease.PARIS5-Bibliotheque electronique (751069902) / SudocPARIS-BIUM-Bib. électronique (751069903) / SudocSudocFranceF

Stress induced polarization of immune-neuroendocrine phenotypes in Gallus gallus

Immune-neuroendocrine phenotypes (INPs) stand for population subgroups differing in immune-neuroendocrine interactions. While mammalian INPs have been characterized thoroughly in rats and humans, avian INPs were only recently described in Coturnix coturnix (quail). To assess the scope of this biological phenomenon, herein we characterized INPs in Gallus gallus (a domestic hen strain submitted to a very long history of strong selective breeding pressure) and evaluated whether a social chronic stress challenge modulates the individuals’ interplay affecting the INP subsets and distribution. Evaluating plasmatic basal corticosterone, interferon-γ and interleukin-4 concentrations, innate/acquired leukocyte ratio, PHA-P skin-swelling and induced antibody responses, two opposite INP profiles were found: LEWIS-like (15% of the population) and FISCHER-like (16%) hens. After chronic stress, an increment of about 12% in each polarized INP frequency was found at expenses of a reduction in the number of birds with intermediate responses. Results show that polarized INPs are also a phenomenon occurring in hens. The observed inter-individual variation suggest that, even after a considerable selection process, the population is still well prepared to deal with a variety of immune-neuroendocrine challenges. Stress promoted disruptive effects, leading to a more balanced INPs distribution, which represents a new substrate for challenging situations.Fil: Nazar, Franco Nicolas. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; ArgentinaFil: Estevez, Inma. Centro de Investigación. Neiker - Tecnalia; EspañaFil: Correa, Silvia Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Marin, Raul Hector. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentin

Impact of Enriched Environment on Murine T Cell Differentiation and Gene Expression Profile

This Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permissionThis study was not supported by any grant funding. GP and SB are supported by QMUL Principal and MRC PhD studentships, respectively

Inducible nitric oxide synthase inhibition by 1400W limits pain hypersensitivity in a neuropathic pain rat model

Peripheral neuropathic pain (PNP), resulting from injury to or dysfunction of a peripheral nerve, is a major health problem that affects 7–8% of the population. It is inadequately controlled by current drugs and is characterized by pain hypersensitivity, which is believed to be attributable to sensitization of peripheral and CNS neurons by various inflammatory mediators. Here we examined, in a rat model of PNP: (i) whether reducing levels of nitric oxide (NO) with 1400W, a highly selective inhibitor of inducible NO synthase (iNOS), would prevent or attenuate pain hypersensitivity; and (ii) the effects of 1400W on plasma concentrations of several cytokines that are secreted after iNOS upregulation during chronic pain states. The L5 spinal nerve axotomy (SNA) model of PNP was used, and 1400W (20 mg kg−1) was administered i.p . at 8 h intervals for 3 days starting at 18 h post‐SNA. Changes in plasma concentrations of 12 cytokines in SNA rats treated with 1400W were examined using multiplex enzyme‐linked immunosorbent assay. The SNA rats developed behavioural signs of mechanical and heat hypersensitivity. Compared with the vehicle/control, 1400W significantly: (i) limited development of mechanical hypersensitivity at 66 h post‐SNA and of heat hypersensitivity at 42 h and at several time points tested thereafter; and (ii) increased the plasma concentrations of interleukin (IL)‐1α, IL‐1β and IL‐10 in the SNA rats. The findings suggest that 1400W might exert its analgesic effects by reducing iNOS and altering the balance between the pro‐inflammatory (IL‐1β and IL‐1α) and anti‐inflammatory (IL‐10) cytokines and that therapies targeting NO or its enzymes might be effective for the treatment of PNP

Immune neuroendocrine phenotypes in Coturnix coturnix: Do avian species show LEWIS/FISCHER-like profiles?

Immunoneuroendocrinology studies have identified conserved communicational paths in birds and mammals, e.g. the Hypothalamus-Pituitary-Adrenal axis with anti-inflammatory activity mediated by glucocorticoids. Immune neuroendocrine phenotypes (INPs) have been proposed for mammals implying the categorization of a population in subgroups underlying divergent immune-neuroendocrine interactions. These phenotypes were studied in the context of the LEWIS/FISCHER paradigm (rats expressing high or low pro-inflammatory profiles, respectively). Although avian species have some common immunological mechanisms with mammals, they have also evolved some distinct strategies and, until now, it has not been studied whether birds may also share with mammals similar INPs. Based on corticosterone levels we determined the existence of two divergent groups in Coturnix coturnix that also differed in other immune-neuroendocrine responses. Quail with lowest corticosterone showed higher lymphoproliferative and antibody responses, interferon-γ and interleukin-1β mRNA expression levels and lower frequencies of leukocyte subpopulations distribution and interleukin-13 levels, than their higher corticosterone counterparts. Results suggest the existence of INPs in birds, comparable to mammalian LEWIS/FISCHER profiles, where basal corticosterone also underlies responses of comparable variables associated to the phenotypes. Concluding, INP may not be a mammalian distinct feature, leading to discuss whether these profiles represent a parallel phenomenon evolved in birds and mammals, or a common feature inherited from a reptilian ancestor millions of years ago

La NO-synthase de type 2 (une cible thérapeutique pour le traitement du traumatisme crânien ?)

L objectif de ce travail était de déterminer si la NO-synthase de type 2 (NOS2) constitue une stratégie thérapeutique pour le traitement du traumatisme crânien (TC). Nous avons montré que notre modèle de TC par percussion de fluide chez le rat entraîne, durant les trois premiers jours, une induction de la NOS2 ainsi qu un déficit neurologique, une augmentation de la perméabilité de la BHE, un œdème cérébral et une lésion cérébrale. Un traitement par des inhibiteurs de NOS2 conduit à une réduction du déficit neurologique et de la lésion cérébrale avec une large fenêtre thérapeutique mais n'a pas d'effet anti-œdémateux. De plus, nous avons montré que les taux plasmatiques des produits terminaux du NO (NOx) et de proline sont corrélés au score neurologique et pourraient être des marqueurs permettant d évaluer la sévérité du TC. En conclusion, nous avons montré que l inhibition de la NOS2 constituent une stratégie thérapeutique pour le traitement en phase aiguë du TC avec une large fenêtre thérapeutique.The aim of this study was to determine if inhibition of iNOS constitutes a promising strategy for the treatment of traumatic brain injury (TBI). We showed that during the first three days following TBI in a rat model of fluid percussion brain injury, there was an induction of iNOS as well as a neurological deficit, an increase of the permeability of blood brain barrier, a cerebral edema and a brain lesion. Treatments with iNOS inhibitors reduced the neurological deficit and the brain lesion with a broad therapeutic window without having any effect on cerebral edema. Moreover, we showed that the plasma level of nitric oxide end products (NOx) and that of proline were correlated with the neurological score, which could be considered as markers of TBI severity. In conclusion, we showed that the inhibition of iNOS could be a therapeutic strategy for the treatment of TBI at its acute phase.PARIS-BIUP (751062107) / SudocSudocFranceF

A Disintegrin And Metalloprotease 10 expression within the murine central nervous system

International audienceA Disintegrin And Metalloprotease 10 (ADAM10), is able to control several important physiopathological processes through the shedding of a large number of protein substrates. Although ADAM10 plays a crucial role in the central nervous system (CNS) development and function, its protein distribution in the CNS has not been fully addressed. Here, we described the regional and cellular ADAM10 protein expression in C57BL/6 mice examined by immunofluorescence 1) throughout the adult mouse brain, cerebellum and spinal cord in vivo and 2) in different cell types as neurons, astrocytes, oligodendrocytes and microglia in vitro. We observed ADAM10 expression through the whole CNS, with a strong expression in the hippocampus, in the hypothalamus and in the cerebral and piriform cortex in the brain, in the Purkinje and in granular cell layers in the cerebellum and in the spinal cord to a lower extent. In vivo, ADAM10 protein expression was mainly found in neurons and in some oligodendroglial cell populations. However, in primary cultures we observed ADAM10 expression in neurons, oligodendrocytes, astrocytes and microglia. Interestingly, ADAM10 was not only found in the membrane but also in cytoplasmic vesicles and in the nucleus of primary cultured cells. Overall, this work highlights a wide distribution of ADAM10 throughout the CNS. The nuclear localization of ADAM10, probably due to its intracellular domain, emphasizes its role in cell signalling in physiological and pathological conditions. Further investigations are required to better elucidate the role of ADAM10 in glial cells

Localization and characterization of interleukin-1 receptors in the islets of Langerhans from control and nonobese diabetic mice.

International audienceNumerous in vivo and in vitro studies have shown the effects of interleukin-1 (IL-1) on insulin and glucagon secretion. To understand the mechanism of these effects, we performed localization and characterization of IL-1 receptors (IL-1R) in pancreas using a quantitative autoradiography method and recombinant human (rh) [125I]IL-1 alpha as a ligand. Frozen sections of pancreas were studied in control (C3H/He) and nonobese diabetic (NOD) mice (a model of autoimmune type I diabetes). Compared to splenic IL-1R, a very high density of specific IL-1R (> 4-fold that in spleen) was found on the islets of Langerhans in both strains. In C3H/He mice, competition experiments demonstrated the presence of one high affinity binding site (Ki = 3.4 and 3.2 x 10(-10) M; binding capacity, 137 and 122 fmol/mg protein for rhIL-1 alpha and rhIL-1 beta, respectively), comparable to type I IL-1R described on T-lymphocytes. In prediabetic NOD mice, these IL-1R were expressed with the same density, affinity, and specificity as in the control strain. Before the onset of diabetes, the expression of IL-1R protein on the islet cells appears to be entirely normal. In contrast, in diabetic NOD mice, IL-1R are sharply decreased, correlating with the intensity of islet destruction. In conclusion, the localization and high density of IL-1R on the mouse islets of Langerhans complement previous studies showing the presence of messenger RNA for type I IL-1R on the islets of Langerhans. These results support a direct physiological effect of IL-1 on pancreatic hormones, such as insulin and glucagon, and a potential role of IL-1R in the pathogenesis of type I diabetes